This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. Looking ahead, 2025 could represent a major turning point for the pharmaceutical sector.
Pharmaceuticalcompanies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. To address these challenges, many companies outsource their clinical trials to contract research organizations (CROs) with established protocols, global reach, and therapeutic area expertise1.
The pharmaceutical landscape is evolving rapidly, with small and medium-sized biotech companies increasingly taking center stage in innovation. In 2017, small and medium-sized biotech companies accounted for 51% of FDA market approvals, while large pharmacompanies were the originators in only 28% of approvals[4].
But in today’s highly regulated environment, it is more important than ever to make sure that HCP engagement plans are compliant with anti-kickback laws. Since KOLs play such a critical role, engaging with the right KOLs is a key strategy for pharmaceuticalcompanies to stay ahead of the game.
The algae-derived non-digestible oligosaccharides can also influence the expression of cytokines that regulate the immune system. Pharmaceuticalcompanies meanwhile need to reinvest in natural product research. 9 Academic scientists researching natural products often struggle with the pitfalls of drug development.
Drug Pricing, Global Diversity Strategies, & Emerging AI Applications Each year, we compile our predictions to provide life sciences, pharmaceutical, and healthcare organizations with a comprehensive look at emerging industry trends and dynamics to help them prepare for the year ahead.
Hartfield previously served as CEO of Vitae Pharmaceuticals prior to its acquisition by Allergan. X4 Pharmaceuticals – Diego Cadavid was named chief medical officer of Boston-based X4 Pharmaceuticals. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.
Ensuring access to safe and effective treatments is the main challenge faced by pharmaceuticalcompanies big and small. Value-added medicines offer an efficient method to meet the needs of patients while stimulating innovation in the pharmaceutical industry. What is a value-added medicine? To comply with the law.
The sponsor is the pharmaceuticalcompany conducting the trial. The standard for the audit used depends on the type of vendor and would include the applicable regulations and ICH guidelines. A: Working in a pharmaceuticalcompany is the best way to learn this. A: This does not usually happen.
Regulators traditionally want to see a single, stable, well-characterized drug before giving the green light for it to be tested in a clinical trial, not dozens of different viruses; let alone ones that are best found in unappealing places like sewage , hospital waste, or bird poop. 4 But the same barriers still exist today. .
Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib Published in Pharmaceutical Research This paper reports on an innovative way for using existing non-cancer drugs to reduce the dose and to potentially improve efficacy of approved expensive anticancer drugs.
"5 Key Considerations for Valuing PharmaCompanies As the pharmaceutical industry continues to evolve, accurately valuing pharmacompanies has become increasingly complex. Patent Portfolio Strength : A strong patent portfolio can significantly impact a company's valuation.
Before I show you what this breakthrough pain solution is, I want to let you in on the “dirty little secret” of the pharmaceutical industry. ” Here’s The Dirty Little Secret Of The Pharmaceutical Industry. Why did the big pharmaceuticals maker under express or hide the potential for addictions with opiates.
The journey from distrust to collaboration among industry, academia and regulators will expedite integration, minimise clinical failures and enhance economic sustainability. Techbio companies have initiated this approach. FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine.
The reason for this is still not understood and many regulators may want it to be explained before authorizing it for broader use. It also calls for ending the tax deductions that pharmaceuticalcompanies can take for the amount of money it spends on advertising its medications.
They are:
• BioMarin Pharmaceutical.
The case is Vanda Pharmaceuticals, Inc. 27, 2023), and the plaintiff was a pharmaceuticalcompany that wanted to know what the FDA really thought of its drug. The company lodged a request under the Freedom of Information Act (“FOIA”), which the FDA refused. 22-cv-938, 2023 U.S. LEXIS 51853 (D.D.C. Here is what happened.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content